TREM2⁺ tumor-associated macrophages in cancer: Context-dependent biology, biomarkers, and precision immunotherapy

Study limitation reported by the research below: “Therapeutic strategies discussed (antibody-based targeting, macrophage reprogramming) are in early translational or preclinical stages; no approved therapies directly targeting TREM2 in cancer are established.”